116 related articles for article (PubMed ID: 26768118)
1. TNF alpha signaling is associated with therapeutic responsiveness to vascular disrupting agents in endocrine tumors.
Hantel C; Ozimek A; Lira R; Ragazzon B; Jäckel C; Frantsev R; Reincke M; Bertherat J; Mussack T; Beuschlein F
Mol Cell Endocrinol; 2016 Mar; 423():87-95. PubMed ID: 26768118
[TBL] [Abstract][Full Text] [Related]
2. Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC).
Casaburi I; Avena P; De Luca A; Chimento A; Sirianni R; Malivindi R; Rago V; Fiorillo M; Domanico F; Campana C; Cappello AR; Sotgia F; Lisanti MP; Pezzi V
Oncotarget; 2015 Sep; 6(28):25135-48. PubMed ID: 26312764
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.
Jain M; Zhang L; He M; Patterson EE; Nilubol N; Fojo AT; Joshi B; Puri R; Kebebew E
Cancer; 2012 Nov; 118(22):5698-708. PubMed ID: 22570059
[TBL] [Abstract][Full Text] [Related]
4. A20 suppresses hepatocellular carcinoma proliferation and metastasis through inhibition of Twist1 expression.
Chen H; Hu L; Luo Z; Zhang J; Zhang C; Qiu B; Dong L; Tan Y; Ding J; Tang S; Shen F; Li Z; Wang H
Mol Cancer; 2015 Nov; 14():186. PubMed ID: 26538215
[TBL] [Abstract][Full Text] [Related]
5. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F
Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813
[TBL] [Abstract][Full Text] [Related]
6. Liposomal doxorubicin-based treatment in a preclinical model of adrenocortical carcinoma.
Hantel C; Lewrick F; Reincke M; Süss R; Beuschlein F
J Endocrinol; 2012 May; 213(2):155-61. PubMed ID: 22407999
[TBL] [Abstract][Full Text] [Related]
7. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
[TBL] [Abstract][Full Text] [Related]
8. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.
Zhu Y; Wang M; Zhao X; Zhang L; Wu Y; Wang B; Hu W
Oncotarget; 2017 Apr; 8(14):22825-22834. PubMed ID: 28423559
[TBL] [Abstract][Full Text] [Related]
9. Up-regulated A20 promotes proliferation, regulates cell cycle progression and induces chemotherapy resistance of acute lymphoblastic leukemia cells.
Chen S; Xing H; Li S; Yu J; Li H; Liu S; Tian Z; Tang K; Rao Q; Wang M; Wang J
Leuk Res; 2015 Sep; 39(9):976-83. PubMed ID: 26159495
[TBL] [Abstract][Full Text] [Related]
10. The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts.
Milanović D; Braun F; Weber W; Grosu AL; Behe M; Niedermann G
BMC Cancer; 2012 Jun; 12():242. PubMed ID: 22695475
[TBL] [Abstract][Full Text] [Related]
11. Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma.
Kuai R; Subramanian C; White PT; Timmermann BN; Moon JJ; Cohen MS; Schwendeman A
Int J Nanomedicine; 2017; 12():6581-6594. PubMed ID: 28919755
[TBL] [Abstract][Full Text] [Related]
12. cAMP-dependent protein kinase activation inhibits proliferation and enhances apoptotic effect of tumor necrosis factor-alpha in NCI-H295R adrenocortical cells.
Liu J; Li XD; Ora A; Heikkilä P; Vaheri A; Voutilainen R
J Mol Endocrinol; 2004 Oct; 33(2):511-22. PubMed ID: 15525605
[TBL] [Abstract][Full Text] [Related]
13. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.
Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M
Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666
[TBL] [Abstract][Full Text] [Related]
14. A20 inhibits human salivary adenoid cystic carcinoma cells invasion via blocking nuclear factor-kappaB activation.
Zhang B; Guan CC; Chen WT; Zhang P; Yan M; Shi JH; Qin CL; Yang Q
Chin Med J (Engl); 2007 Oct; 120(20):1830-5. PubMed ID: 18028781
[TBL] [Abstract][Full Text] [Related]
15. Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.
Hermsen IG; Haak HR; de Krijger RR; Kerkhofs TM; Feelders RA; de Herder WW; Wilmink H; Smit JW; Gelderblom H; de Miranda NF; van Eijk R; van Wezel T; Morreau H
Eur J Endocrinol; 2013 Jul; 169(1):51-8. PubMed ID: 23585556
[TBL] [Abstract][Full Text] [Related]
16. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment.
Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235
[TBL] [Abstract][Full Text] [Related]
17. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
Ronchi CL; Sbiera S; Kraus L; Wortmann S; Johanssen S; Adam P; Willenberg HS; Hahner S; Allolio B; Fassnacht M
Endocr Relat Cancer; 2009 Sep; 16(3):907-18. PubMed ID: 19240185
[TBL] [Abstract][Full Text] [Related]
18. Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study.
Fiorentini C; Fragni M; Perego P; Vezzoli S; Bonini SA; Tortoreto M; Galli D; Claps M; Tiberio GA; Terzolo M; Missale C; Memo M; Procopio G; Zaffaroni N; Berruti A; Sigala S
J Clin Endocrinol Metab; 2016 Dec; 101(12):4594-4602. PubMed ID: 27626976
[TBL] [Abstract][Full Text] [Related]
19. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.
Head M; Jameson MB
Expert Opin Investig Drugs; 2010 Feb; 19(2):295-304. PubMed ID: 20050824
[TBL] [Abstract][Full Text] [Related]
20. n-3 polyunsaturated fatty acids abrogate mTORC1/2 signaling and inhibit adrenocortical carcinoma growth in vitro and in vivo.
Liu J; Xu M; Zhao Y; Ao C; Wu Y; Chen Z; Wang B; Bai X; Li M; Hu W
Oncol Rep; 2016 Jun; 35(6):3514-22. PubMed ID: 27035283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
